Progression to Dysplasia in Barrett’s Esophagus
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2005 Feb 15;71(4):785-786.
Clinical Question: Which men with Barrett’s esophagus are at greatest risk of progression to high-grade dysplasia or cancer?
Setting: Outpatient (specialty)
Study Design: Cohort (prospective)
Synopsis: The authors identified 550 patients who underwent endoscopy for any reason and were diagnosed with Barrett’s esophagus between 1990 and 2003. The study took place at a Veterans Affairs hospital, 99 percent of participants were men, and 93 percent were white. Patients ranged in age from 28 to 86 years (mean age = 63 years). At the initial endoscopy, 77 percent had no dysplasia, 18 percent had low-grade dysplasia, and 5 percent had unifocal high-grade dysplasia. Helicobacter pylori infection was absent in 345 patients, present in 72 patients, and a history of H. pylori eradication was identified in 60 patients. Patients with cancer, dysplasia-associated lesion or mass, or intramucosal cancer at enrollment were excluded (n = 28).
Of the 550 patients initially identified, 28 had a diagnosis of malignancy, 173 had no follow-up endoscopy, 15 died from other causes, and 10 were lost to follow-up, leaving 324 for the study. It is unknown whether outcomes were assessed blindly. Patients with newly diagnosed low-grade dysplasia or unifocal high-grade dysplasia had optimized medical therapy and were re-endoscoped at 12 to 24 weeks (for patients with low-grade dysplasia) or four to eight weeks (for patients with high-grade dysplasia). Patients with persistent high-grade dysplasia had surveillance at three- to six-month intervals, while those with low-grade dysplasia or regression to normal had surveillance at six- to 12-month intervals. Although patients were followed for up to 130 months based on the Kaplan-Meier curves, the mean or median duration of follow-up or the number of follow-up endoscopies was not given.
Results were presented in several ways. Independent risk factors for high-grade dysplasia or cancer at the initial endoscopy were increased age, greater length of Barrett’s esophagus (especially greater than 6 cm), and never having been diagnosed with H. pylori infection. The independent risk factors for progression of Barrett’s esophagus to high-grade dysplasia or cancer were length, initial histology, histology at follow-up, and H. pylori status. The risk was low for patients with no dysplasia on the initial endoscopy (i.e., 2.4 percent if the length is less than 6 cm; 6.8 percent if the length is more than 6 cm) or with low-grade dysplasia only (i.e., 5.3 percent with length of less than 6 cm). All other groups had at least a 35 percent risk of progression.
Bottom Line: Patients with no dysplasia on the initial endoscopy or with low-grade dysplasia only and Barrett’s esophagus length of less than 6 cm have a very low risk of progression to high-grade dysplasia or malignancy. (Level of Evidence: 2b)
Weston AP, et al. Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis. Am J Gastroenterol. September 2004;99:1657–66.
Used with permission from Ebell M. Length and dysplasia predict BE progression in men. Accessed online November 24, 2004, at: http://www.InfoPOEMs.com.
Want to use this article elsewhere? Get Permissions